Clinical trials: Lymphomas,
Acute Lymphoblastic Leukemia
Treatment of Adult ALL With an MRD-directed Programme.
The study aims to optimize the concept of risk-oriented postremission consolidation therapy, by offering (i) standard consolidation-maintenance to patients at lowest risk of relapse as defined by MRD(Minimal Residual Disease)…
- Trial name
- NCT00358072
- Testing
- Postremission consolidation based on MRD status
- Where
- 15 sites in Italy
- Volunteers
- 280 people
- Sponsor
- Northern Italy Leukemia Group
Grade I or II Essential Hypertension
Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
The objective of this study is to compare the efficacy and safety of combined administration of TAK-536CCB (Fix-dose combination of Azilsartan and Amlodipine) and Hydrochlorothiazide (HCTZ) with those of TAK-536CCB in patients…
- Trial name
- NCT02072330
- Testing
- TAK-536CCB, TAK-536CCB + Hydrochlorothiazide, Hydrochlorothiazide
- Where
- 13 sites in Japan
- Volunteers
- 353 people
- Sponsor
- Takeda
Non-small Cell Lung Cancer
A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib
This randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of XZP-3621 versus crizotinib and to evaluate the pharmacokinetics of XZP-3621 in Chinese participants with treatment-naive…
- Trial name
- NCT05204628
- Testing
- XZP-3621, Crizotinib
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Lymphoma, Non-Hodgkin
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models.
- Trial name
- NCT00088530
- Testing
- pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
- Where
- 99 sites in United States, Argentina and 18 more
- Volunteers
- 140 people
- Sponsor
- CTI BioPharma
Leukemia, Lymphoma
Blood Samples to Identify Biomarkers of Busulfan
Specific Aim 1: To determine whether endogenous metabolomics-based biomarkers obtained before IV BU administration can predict IV BU clearance. Specific Aim 2: To characterize IV BU metabolism by metabolomics.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Immunodeficiency
- Trial name
- NCT02291965
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Fred Hutchinson Cancer Center
Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Daptomycin is a new antimicrobial agent which has activity against resistant Gram positive cocci including MRSA. The phase 3 clinical trials for skin and soft tissue infections (SSTI) with Staphylococci and Streptococci have…
- Conditions
- Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections, Fournier's Gangrene
- Trial name
- NCT00261807
- Testing
- Daptomycin 6mg/kg/day
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Maryland, Baltimore
Primary Central Nervous System Lymphoma (PCNSL), CNS Lymphoma Treatment
Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma
High-dose methotrexate (HD-MTX) remains the foundation of treatment for primary central nervous system lymphoma (PCNSL), but outcomes are suboptimal.
- Trial name
- NCT06946407
- Testing
- Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation
- Where
- China
- Volunteers
- 41 people
- Sponsor
- FengYan Jin
Chemotherapy-induced Symptomatic Anemia, Solid Tumors
Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.
- Conditions
- Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies, Lymphomas
- Trial name
- ORHEO (NCT02140736)
- Testing
- Epoetin biosimilar
- Where
- 172 sites in France
- Volunteers
- 2,333 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Ph^1^, Absent
Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
The cure rate for childhood acute lymphoblastic leukemia (ALL) has increased significantly in recent decades and expected cure rates now exceed 85%.
- Conditions
- Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Ph^1^, Absent, B-cell Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT01990807
- Testing
- Idarubicin(IDA)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
Non-Hodgkin's Lymphoma, Leukemia
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.
- Conditions
- Non-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
- Trial name
- NCT00709592
- Testing
- Thymoglobulin, Total-Body Irradiation, Allogeneic PBSCT or BMT
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Virginia Commonwealth University
Improve the Radiotherapy Planning Process
FDG PET-CT for Lymphoma Radiotherapy Planning Version 1.3
Chemotherapy followed by radiotherapy is used to treat early stage lymphomas with excellent cure rates. However, a significant proportion of these patients develop cancers and heart diseases years later as a result of the…
- Trial name
- NCT01999998
- Testing
- Radiotherapy
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Crohn's Disease, Peritoneal Carcinomatosis With Intestinal Occlusion
CAre of Patients With PArenteral Nutrition At Home
This research aims to give an overview of a number of aspects related to the quality of care for adult patients on home parenteral nutrition.
- Conditions
- Crohn's Disease, Peritoneal Carcinomatosis With Intestinal Occlusion, Radiation Enteritis, Chronic Diarrhea
- Trial name
- CAPANAH (NCT01545063)
- Where
- 13 sites in Belgium
- Volunteers
- 39 people
- Sponsor
- KU Leuven
Lymphoma, Follicular
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate whether treatment with rituximab plus sargramostim will be more effective than rituximab alone.
- Trial name
- PREMIER (NCT00308087)
- Testing
- Sargramostim (Leukine), Rituximab
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- Genzyme, a Sanofi Company
Marginal Zone Lymphoma
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
This is a single-arm, multicenter, prospective, phase II study. The primary objective is to assess the efficacy and safety of orelabrutinib in treatment-naïve patients with marginal zone lymphoma.
- Trial name
- MZL-IIT-O (NCT07441993)
- Testing
- Orelabrutinib
- Where
- 14 sites in China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Mammary Cancer, Lymphoma
The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy
The purpose of the trail is to evaluate the efficacy and safety of PEG-rhG-CSF in primary prophylaxis and secondary prophylaxis of neutropenia after chemotherapy.
- Conditions
- Mammary Cancer, Lymphoma, Bone Tumour, Gynecological Tumors
- Trial name
- NCT02905916
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 217 people
- Sponsor
- Peking University
B-cell Lymphoma, Hodgkin Lymphoma
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma
This study aims to assess the feasibility of predicting patient outcomes at 1 year and 2 years after the end of first-line treatment using "liquid biopsy" (monitoring of circulating tumor DNA, ctDNA), compared to the currently…
- Trial name
- CELERITY (NCT06744075)
- Testing
- Blood assessment
- Where
- 2 sites in France
- Volunteers
- 108 people
- Sponsor
- Centre Henri Becquerel
B Cell Lymphoma
The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
This is a clinical study to observe the safety and feasibility of chimeric antigen receptor 19 (CART-19) cells in relapsed and refractory patients with CD19+ B cell lymphoma.
- Trial name
- NCT03101709
- Testing
- Cyclophosphamide, Fludarabine, CART-19
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Lymphoma
Samsung Medical Center-Lymphoma Cohort Study-II
The purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.
- Trial name
- SMC-LCS-II (NCT01877109)
- Where
- South Korea
- Volunteers
- 1,358 people
- Sponsor
- Samsung Medical Center
Lymphoma
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
This phase II clinical trial studies how well yttrium Y 90 ibritumomab tiuxetan, rituximab, and high-dose chemotherapy followed by peripheral blood stem cell transplant in treating patients with relapsed B-cell non-Hodgkin…
- Trial name
- NCT00695409
- Testing
- rituximab, carmustine, cytarabine
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- City of Hope Medical Center
Low-Grade Lymphoma
Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Current therapies for Low-grade Non-Hodgkin's Lymphoma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Low-grade Non-Hodgkin's…
- Trial name
- NCT00003499
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Burzynski Research Institute
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.